New Treatment Offers Hope for Glioblastoma Patients

A novel treatment approach is emerging for patients battling glioblastoma, a highly aggressive brain cancer known for its poor prognosis. This breakthrough, spearheaded by Andrew Brenner, MD, PhD, a neuro-oncologist at UT Health San Antonio, may significantly improve survival rates and quality of life for those diagnosed with this devastating illness.

Glioblastoma is notorious for its rapid progression and resistance to conventional therapies. The average survival for patients is approximately 12 to 18 months, with many high-profile cases, including those of Senators Ted Kennedy and John McCain, as well as Beau Biden, underscoring the disease’s lethal nature. Current treatment primarily involves radiation, which, while effective to some extent, poses risks to surrounding brain tissue, limiting its applicability.

Innovative Targeting Method

Dr. Brenner’s research focuses on a tailored molecule designed to enhance the delivery of radiation directly to the tumor site. This molecule binds with liquid radiation, making it fat-soluble and enabling encapsulation in tiny fat bubbles known as liposomes. These liposomes are delivered to the tumor via catheters resembling coffee straws, facilitating a precise application of high doses of radiation.

“What you see is very, very high doses where you put it and then a fast drop-off in the areas after it,” Dr. Brenner explained. This targeted approach aims to effectively destroy the tumor while sparing healthy surrounding tissue, which is a significant advancement over traditional methods.

Initial studies conducted on rats demonstrated promising results. Pathologists examining the brains after treatment noted, “If you tell me there was a tumor there, I have to believe you, but there’s really nothing. It’s just a hole,” indicating a remarkable absence of tumor presence and tissue damage.

Human Trials and Patient Experience

Encouragingly, this innovative treatment is now being tested in human clinical trials. Patients involved in the trials report a more manageable experience compared to standard radiation therapy, which typically requires frequent visits to healthcare facilities over several weeks. According to Dr. Brenner, “With this, they have the catheters placed. The next day, they have the infusion, and then they go home, and that’s it.”

The potential impact of this advancement is profound. Over the past three decades, the projected lifespan for glioblastoma patients has increased by only about six months. Dr. Brenner aims to change that trajectory. “I would love a cure. That’s obviously aspirational,” he stated. “But each patient that I can give an extra month with their children or their grandkids or their spouse or contributing to our planet is important.”

As research continues, the hope remains that this treatment will provide not just longer lives, but also an enhanced quality of life for glioblastoma patients and their families.

This development is part of a collaborative effort between Texas Public Radio (TPR) and The University of Texas Health Science Center at San Antonio, highlighting how scientific advancements in San Antonio aim to reshape medical practices globally.